Print

FDA Advisory Panel Backs Approval of Johnson & Johnson (JNJ)'s Hepatitis C Drug  
10/25/2013 6:53:30 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

An advisory committee of the U.S. Food and Drug Administration voted unanimously to approve Johnson & Johnson's hepatitis C drug, J&J said on Thursday. The panel voted 19-0 in favor of the drug, simeprevir, which was tested in combination with standard hepatitis C drugs, peginterferon-alpha and ribavirin. The drug is being developed by J&J unit Janssen Research & Development LLC. It is being tested in adults who failed previous interferon-based therapy or had not received medication at all.

Help employers find you! Check out all the jobs and post your resume.

//-->